Type of organ
POPULARITY
70 episodes with biliary
13 episodes with biliary
6 episodes with biliary
7 episodes with biliary
8 episodes with biliary
7 episodes with biliary
8 episodes with biliary
12 episodes with biliary
8 episodes with biliary
7 episodes with biliary
4 episodes with biliary
3 episodes with biliary
7 episodes with biliary
4 episodes with biliary
3 episodes with biliary
5 episodes with biliary
3 episodes with biliary
8 episodes with biliary
4 episodes with biliary
2 episodes with biliary
12 episodes with biliary
3 episodes with biliary
3 episodes with biliary
2 episodes with biliary
3 episodes with biliary
2 episodes with biliary
3 episodes with biliary
7 episodes with biliary
3 episodes with biliary
3 episodes with biliary
3 episodes with biliary
2 episodes with biliary
2 episodes with biliary
2 episodes with biliary
7 episodes with biliary
3 episodes with biliary
Biliary tract cancer (BTC) presents a complex puzzle for the interprofessional healthcare team. With its diverse subtypes and unique molecular features, diagnosis and treatment require a personalized approach. Stay ahead of the curve with insights from leading experts, Dr. Anjana Pillai and Dr. Rachna Shroff, as they explore the latest genomic research, targeted therapies, and emerging treatment strategies in this dynamic podcast. Listen now to hear the Multidisciplinary Task Force perspective and strategies to optimize patient care in this rapidly evolving landscape. Click here to claim your credit for this podcast:
In this episode, we review the high-yield topic Primary Biliary Cholangitis from the Gastrointestinal section at Medbullets.comFollow Medbullets on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbulletsLinkedin: https://www.linkedin.com/company/medbullets
Discover how to recognize the burden of primary biliary cholangitis (PBC)-associated pruritus and make evidence-based treatment decisions to improve patient quality of life. Credit available for this activity expires: 5/22/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/breaking-news-what-youre-itching-know-about-primary-biliary-2025a1000clq?ecd=bdc_podcast_libsyn_mscpedu
In this episode, we review the high-yield topic of Primary Biliary Cholangitis from the Gastrointestinal section.Follow Medbullets on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbullets
Biliary tract cancers are a group of rare cancers with limited treatment options and generally poor outcomes because most patients are diagnosed at an advanced stage. There are efforts to address that through the development of early detection tools. And the use of biomarker testing can today match as many as half of these patients to a targeted therapy, although it's critical to make people aware of the importance of this. We spoke to Rachna Shroff, associate director of clinical investigations of the gastrointestinal clinical research team at the University of Arizona Cancer Center, about biliary tract cancers, the importance of biomarker testing, and what can be done to improve outcomes for people with these rare cancers.
Welcome to another episode of the Oncology Brothers podcast! In this episode, Drs. Rohit and Rahul Gosain, both practicing community medical oncologists, continue their discussion on HER2-positive biliary tract cancer. They are joined by Dr. Shubham Pant from MD Anderson, who shares his expertise on this rapidly evolving field. In this episode, we cover: • The importance of HER2 testing in biliary tract cancers, including intrahepatic and extrahepatic cholangiocarcinomas and gallbladder cancers. • Who should be tested for HER2 positivity and how to classify HER2-positive disease. • The role of next-generation sequencing (NGS) and immunohistochemistry (IHC) in determining HER2 status. • Current treatment options for HER2-positive biliary tract cancer, including the latest clinical trials and approved therapies like trastuzumab deruxtecan and zanidatamab. • The significance of patient-centered decision-making and managing side effects associated with these treatments. • Insights into the potential for brain metastases in biliary tract cancer and the importance of ongoing surveillance. Join us as we delve into the latest data and strategies for managing HER2-positive biliary tract cancer, and stay tuned for our next episode where we will discuss side effects and management of these therapies. Accreditation/Credit Designation Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Physicians' Education Resource®, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Acknowledgment of Commercial Support This activity is supported by an educational grant from Jazz Pharmaceuticals, Inc. Link to gain CME credits from this activity: https://www.gotoper.com/courses/from-bench-to-bedside-paradigm-shifts-in-her2-metastatic-btc-treatment Follow us on social media: • X/Twitter: https://twitter.com/oncbrothers • Instagram: https://www.instagram.com/oncbrothers • Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!
Are you using the best approach for patients with HER2-positive biliary tract cancer (BTC)? Credit available for this activity expires: 4/30/2026 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1002492?ecd=bdc_podcast_libsyn_mscpedu
Featuring perspectives from Dr Mitesh J Borad and Dr Amit Mahipal, including the following topics: Introduction (0:00) Targeted Therapeutic Approaches for Patients with Biliary Tract Cancers (BTCs) — Dr Mahipal (4:59) Integration of Immune Checkpoint Inhibitors into Current BTC Management — Dr Borad (32:16) CME information and select publications
Clinical investigators discuss available data guiding the management of biliary tract cancers. CME information and select publications here.
Clinical investigators discuss available data guiding the management of biliary tract cancers. CME information and select publications here.
Clinical investigators discuss available data guiding the management of biliary tract cancers. CME information and select publications here.
Welcome to the Oncology Brothers podcast! In this episode, Drs. Rohit and Rahul Gosain are joined by Dr. Ghassan Abou-Alfa, a medical oncologist specializing in the hepatobiliary space at Memorial Sloan Kettering. Together, they explored the current treatment landscape of biliary tract cancer, focusing on the advancements in HER2-driven therapies. Key topics discussed included: • The evolution of treatment options for biliary tract cancer, including chemotherapy and immunotherapy. • The significance of genetic testing, including IDH1 mutations, FGFR alterations, and HER2 status. • The role of multidisciplinary collaboration in managing hepatobiliary cancers. • Insights into the latest clinical trials and emerging therapies for HER2-positive biliary tract cancer. Join us as we delve into the complexities of biliary tract cancer and the promising developments in HER2-targeted treatments. Don't forget to check out our next episode, where we will take a deeper dive into the data surrounding HER2 therapies and discuss management strategies for common side effects. YouTube: https://youtu.be/pGiU7JJGNOc Follow us on social media: • X/Twitter: https://twitter.com/oncbrothers • Instagram: https://www.instagram.com/oncbrothers • Website: https://oncbrothers.com/ Subscribe to stay updated on the latest in oncology! #OncologyBrothers #BiliaryTractCancer #HER2 #CancerTreatment #MedicalOncology #CME #Podcast
PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/FEE865. CME/NCPD/AAPA/IPCE credit will be available until March 9, 2026.Innovative Approaches to Manage Primary Biliary Cholangitis: Charting New Courses of Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK and Ipsen Biopharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/FEE865. CME/NCPD/AAPA/IPCE credit will be available until March 9, 2026.Innovative Approaches to Manage Primary Biliary Cholangitis: Charting New Courses of Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK and Ipsen Biopharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/FEE865. CME/NCPD/AAPA/IPCE credit will be available until March 9, 2026.Innovative Approaches to Manage Primary Biliary Cholangitis: Charting New Courses of Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK and Ipsen Biopharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/FEE865. CME/NCPD/AAPA/IPCE credit will be available until March 9, 2026.Innovative Approaches to Manage Primary Biliary Cholangitis: Charting New Courses of Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK and Ipsen Biopharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/FEE865. CME/NCPD/AAPA/IPCE credit will be available until March 9, 2026.Innovative Approaches to Manage Primary Biliary Cholangitis: Charting New Courses of Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK and Ipsen Biopharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/FEE865. CME/NCPD/AAPA/IPCE credit will be available until March 9, 2026.Innovative Approaches to Manage Primary Biliary Cholangitis: Charting New Courses of Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK and Ipsen Biopharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/FEE865. CME/NCPD/AAPA/IPCE credit will be available until March 9, 2026.Innovative Approaches to Manage Primary Biliary Cholangitis: Charting New Courses of Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK and Ipsen Biopharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/FEE865. CME/NCPD/AAPA/IPCE credit will be available until March 9, 2026.Innovative Approaches to Manage Primary Biliary Cholangitis: Charting New Courses of Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK and Ipsen Biopharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.
Featuring perspectives from Prof John Bridgewater, including the following topics: Introduction: Biology and Epidemiology; Classification (0:00) Localized Biliary Tract Cancers (6:25) First-Line Treatment of Metastatic BTC (20:04) HER2-Positive Advanced BTC (24:22) Management of Mixed Hepatocellular Carcinoma/BTC Tumors (43:18) Advanced Cholangiocarcinoma with an FGFR2 Fusion (47:59) Other Important Issues in BTC (52:33) CME information and select publications
Dr John Bridgewater from the UCL Cancer Institute in London, United Kingdom, discusses patient cases and summarizes current treatment approaches for cholangiocarcinoma and other biliary tract cancers. CME information and select publications here.
Dr John Bridgewater from the UCL Cancer Institute in London, United Kingdom, discusses patient cases and summarizes current treatment approaches for cholangiocarcinoma and other biliary tract cancers. CME information and select publications here.
Dr John Bridgewater from the UCL Cancer Institute in London, United Kingdom, discusses patient cases and summarizes current treatment approaches for cholangiocarcinoma and other biliary tract cancers. CME information and select publications here.
Dr John Bridgewater from the UCL Cancer Institute in London, United Kingdom, discusses patient cases and summarizes current treatment approaches for cholangiocarcinoma and other biliary tract cancers. CME information and select publications here.
In today's episode, we had the pleasure of speaking with Rachna Shroff, MD, MS, FASCO, about the phase 3 SWOG S1815 trial (NCT03768414) evaluating the addition of nab-paclitaxel (Abraxane) to gemcitabine and cisplatin in patients with newly diagnosed, advanced biliary tract cancer. Dr Shroff of the interim clinical affairs director, the associate director of Clinical Investigations, and co-lead of the Gastrointestinal Clinical Research Team, at The University of Arizona Cancer Center. She is also a professor in the Department of Medicine, chief of the Division of Hematology/Oncology, medical director for the Oncology Service Line, and associate dean for Clinical and Translational Research at The University of Arizona College of Medicine in Tucson. In our exclusive interview, Dr Shroff discussed the rationale for this research, key efficacy and safety data from the trial, and the potentially wide-reaching future implications of these findings.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/AAJ865. CME/MOC/CE/AAPA/IPCE credit will be available until February 23, 2026.Accelerating Innovation In Biliary Tract Cancer: Restructuring Treatment Models With Immunotherapy & Targeted Platforms In Advanced Disease In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Cholangiocarcinoma Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical education grants from AstraZeneca, Incyte Corporation, Jazz Pharmaceuticals, and Taiho Oncology, Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/AAJ865. CME/MOC/CE/AAPA/IPCE credit will be available until February 23, 2026.Accelerating Innovation In Biliary Tract Cancer: Restructuring Treatment Models With Immunotherapy & Targeted Platforms In Advanced Disease In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Cholangiocarcinoma Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical education grants from AstraZeneca, Incyte Corporation, Jazz Pharmaceuticals, and Taiho Oncology, Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/AAJ865. CME/MOC/CE/AAPA/IPCE credit will be available until February 23, 2026.Accelerating Innovation In Biliary Tract Cancer: Restructuring Treatment Models With Immunotherapy & Targeted Platforms In Advanced Disease In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Cholangiocarcinoma Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical education grants from AstraZeneca, Incyte Corporation, Jazz Pharmaceuticals, and Taiho Oncology, Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/AAJ865. CME/MOC/CE/AAPA/IPCE credit will be available until February 23, 2026.Accelerating Innovation In Biliary Tract Cancer: Restructuring Treatment Models With Immunotherapy & Targeted Platforms In Advanced Disease In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Cholangiocarcinoma Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical education grants from AstraZeneca, Incyte Corporation, Jazz Pharmaceuticals, and Taiho Oncology, Inc.Disclosure information is available at the beginning of the video presentation.
PeerView Immunology & Transplantation CME/CNE/CPE Audio Podcast
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/AAJ865. CME/MOC/CE/AAPA/IPCE credit will be available until February 23, 2026.Accelerating Innovation In Biliary Tract Cancer: Restructuring Treatment Models With Immunotherapy & Targeted Platforms In Advanced Disease In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Cholangiocarcinoma Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical education grants from AstraZeneca, Incyte Corporation, Jazz Pharmaceuticals, and Taiho Oncology, Inc.Disclosure information is available at the beginning of the video presentation.
Better Edge : A Northwestern Medicine podcast for physicians
Aziz Aadam, MD, interventional endoscopist, Daniel Borja-Cacho, MD, transplantation surgeon, and Ahsun Riaz, MD, vascular and interventional radiologist, discuss a complex biliary case involving a patient with advanced stage cancer. They explore the innovative, multidisciplinary approach taken to manage the patient's biliary fistula and hepatic duct obstruction. The physicians highlight the collaborative efforts and advanced techniques that led to a successful outcome and improved quality of life for the patient.
Kris V. Kowdley, MD - Advancing Individualized Treatment Strategies in Patients With Primary Biliary Cholangitis
Kris V. Kowdley, MD - Advancing Individualized Treatment Strategies in Patients With Primary Biliary Cholangitis
Send us a textIn this episode of The Autoimmune RESET podcast, we explore Primary Biliary Cholangitis (PBC), a chronic autoimmune condition that primarily affects the liver. Join me as I unpack the root causes, including genetic predisposition, detoxification challenges, and environmental triggers. We'll delve into the symptoms, how PBC is diagnosed, and its connections to other autoimmune conditions like Sjögren's syndrome and thyroid disorders.You'll also learn about practical, evidence-based strategies for managing PBC naturally. From dietary recommendations and key supplements to lifestyle changes that support liver health, this episode is packed with actionable insights. Plus, we discuss emerging research, including the role of gut health, mitochondrial function, and how personalised approaches can make a difference.Whether you're managing PBC, supporting a loved one, or simply curious about liver health, this episode offers a comprehensive guide to understanding and addressing this complex condition. Tune in to discover how small, strategic changes can have a big impact on your wellbeing.You can learn about the testing packages I offer at The Autoimmunity Nutritionist here.Looking for simple ways to calm your nervous system? Learn more about the Nurosyn hereWant to join my new program, The Inflammation Reset, designed to help you tackle inflammation at its source and reclaim your health? You can learn more here.If you are ready for change, download your free copy of The Autoimmunity Recovery Plan here so you can get started.Or, if you prefer working together 1-2-1 or would like to explore functional testing, you can find all my services here. Thanks for listening! You can join The Autoimmune Forum on Facebook or find me on Instagram @theautoimmunitynutritionist.
Review of the gallbladder and biliary tree for radiology board exams. Download the free study guide and access other radiology educational resources at www.theradiologyreview.com. Prepare to succeed! Mentioned in this episode:Board Vitals Discount CodeReady to ace your exams with Board Vitals? Unlock a 10% discount when you use code RADREVIEW at checkout! Don't miss out—start your journey to success today. Terms and conditions apply.
Review of the gallbladder and biliary tree for radiology board exams. Download the free study guide and access other radiology educational resources at www.theradiologyreview.com. Prepare to succeed!Mentioned in this episode:Instagram AdFollow us on Instagram and X(Twitter) @radrevpodcast.
In today's episode, supported by Jazz Pharmaceuticals, we had the pleasure of speaking with James J. Harding, MD, director of Early Drug Development at Memorial Sloan Kettering Cancer Center, about the FDA approval of zanidatamab-hrii (Ziihera) for patients with HER2-positive metastatic biliary tract cancer. In our exclusive interview, Dr Harding discussed the significance of this approval, marking the first HER2-targeted therapy specifically for biliary tract cancer. He highlighted findings from the pivotal HORIZON BTC-01 trial (NCT04466891), explored how zanidatamab fits into the treatment paradigm, and addressed the role of HER2 profiling in guiding patient selection. Dr Harding also detailed ongoing research into zanidatamab in earlier treatment settings and emphasized its potential to transform care for patients with this challenging disease.
Are you up to date with the latest data on HER2-positive biliary tract cancer (BTC)? Credit available for this activity expires: 12/23/2025 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1002081?ecd=bdc_podcast_libsyn_mscpedu
The FDA's recent accelerated approval of zanidatamab marks a significant breakthrough in the treatment landscape for human epidermal growth factor receptor 2 (HER2)–positive biliary tract cancer (BTC). Following the approval, Dr. James Harding, Associate Attending Physician in the Gastrointestinal Oncology and Early Drug Development Services at Memorial Sloan Kettering Cancer Center, sat down to provide oncology clinicians with insights into its significance and implications for clinical practice.
Several new developments in primary biliary cholangitis (PBC) on available and emerging therapies were presented at AASLD 2024. In these podcasts, Dr. Ashwani K. Singal will discuss the most important breakthroughs in the understanding and treatment of PBC and will provide guidance on their impact.Launch Date: November 26, 2024Release Date: November 26, 2024Expiration Date: October 31, 2025FACULTYAshwani K. Singal, MD, MS, FACG, FAASLD, AGAFProfessor of Medicine, University of LouisvilleTransplant Hepatologist and Staff PhysicianTraeger Transplant Center and Jewish HospitalDirector Clinical Trials, University of LouisvilleThis podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.https://www.practicepointcme.com/CMEHome/clinical-clips174-from-aasld-2024-key-breakthroughs-in-the-treatment-of-primary-biliary-cholangitis-17
Several new developments in primary biliary cholangitis (PBC) on available and emerging therapies were presented at AASLD 2024. In these podcasts, Dr. Ashwani K. Singal will discuss the most important breakthroughs in the understanding and treatment of PBC and will provide guidance on their impact.Launch Date: November 26, 2024Release Date: November 26, 2024Expiration Date: October 31, 2025FACULTYAshwani K. Singal, MD, MS, FACG, FAASLD, AGAFProfessor of Medicine, University of LouisvilleTransplant Hepatologist and Staff PhysicianTraeger Transplant Center and Jewish HospitalDirector Clinical Trials, University of LouisvilleThis podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.https://www.practicepointcme.com/CMEHome/clinical-clips174-from-aasld-2024-key-breakthroughs-in-the-treatment-of-primary-biliary-cholangitis-17
How much do you know about new approved therapies for primary biliary cholangitis (PBC)? Credit available for this activity expires: 11/26/2025 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1001965?ecd=bdc_podcast_libsyn_mscpedu
This podcast features an engaging discussion between Dr. Douglas Dieterich and his patient with long-standing PBC, on the patient's insights and experiences with her disease and treatment. The activity will enable participants to understand the importance of listening to patient perspectives when designing individualized care pathways to alleviate symptoms and improve quality of life.Launch Date: November 21, 2024Release Date: November 21, 2024Expiration Date: October 31, 2025FACULTYDouglas Dieterich, MDDirector, Institute for Liver Medicine at Mount SinaiProfessor of Medicine, Icahn School of Medicine at Mount SinaiThis podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.https://www.practicepointcme.com/CMEHome/patient-voices-in-primary-biliary-cholangitis-a-ce-podcast-series-to-recognize-challenges-reduce-disparities-and-improve-outcomes
Drs. Benjamin Schlechter and Harshabad Singh discuss toxicities in gastroesophageal cancer treatment; explore HER2+ in biliary tract tumors; and touch on the challenges of developing therapies targeting HER2+.
This podcast features an engaging discussion between Dr. David Victor and his patient, with long-standing PBC, on the patient's insights and experiences with her disease and treatment. The activity will enable participants to understand the importance of listening to patient perspectives when designing individualized care pathways to alleviate symptoms and improve quality of life.Launch Date: October 24, 2024Release Date: October 24, 2024Expiration Date: September 30, 2025FACULTYDavid W. Victor III, MDAssociate Professor of Clinical MedicineHouston Methodist Research InstituteAssociate Professor of Clinical MedicineWeill Cornell MedicineThis podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.https://www.practicepointcme.com/CMEHome/patient-voices-in-primary-biliary-cholangitis-a-ce-podcast-series-to-recognize-challenges-reduce-disparities-and-improve-outcomes
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/HFK865. CME/MOC credit will be available until October 3, 2025.Strengthening the Immunotherapy Paradigm in Biliary Tract Cancer: Standardizing Team-Based Strategies With Immune Checkpoint Inhibitors in Advanced Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.
Dr. Rick Greene discusses with Dr. Dana Dominguez the association of adjuvant chemoradiation in resected biliary cancer with improved overall survival compared to chemotherapy alone, as reported in her article, "Adjuvant Chemoradiation in Resected Biliary Adenocarcinoma: Evaluation of SWOG S0809 with a Large National Database.” Article: Adjuvant Chemoradiation in Resected Biliary Adenocarcinoma: Evaluation of SWOG S0809 with a Large National Database | Annals of Surgical Oncology (springer.com)
Featuring slide presentations and related discussion from Dr Lipika Goyal, Dr James J Harding, Dr Milind Javle and Dr Robin K (Katie) Kelley, including the following topics: Current Role of Immunotherapeutic Strategies for Advanced Biliary Tract Cancers (BTCs) — Dr Kelley (0:00) Case: A man in his late 60s with advanced distal cholangiocarcinoma treated with the TOPAZ-1 regimen (13:27) Case: A woman in her early 70s with recurrent gallbladder cancer with biliary obstruction (15:56) Targeting FGFR and IDH Alterations for Advanced BTCs — Dr Goyal (35:00) Case: A woman in her late 30s with FGFR2 fusion-positive intrahepatic cholangiocarcinoma (ICC) (54:25) Case: A man in his late 60s with cholangiocarcinoma metastases to liver and bone (1:01:33) Case: A woman in her 60s with ICC with an IDH1 mutation (1:10:05) Emerging Role of HER2-Targeted Therapy for Advanced BTCs — Dr Harding (1:21:15) Case: A man in his early 40s with cholangiocarcinoma metastatic to the appendix (1:57:25) New Directions in the Management of BTCs — Dr Javle (2:01:09) CME information and select publications
Dr Lipika Goyal from Stanford Cancer Center in Palo Alto, California, Dr James J Harding from Memorial Sloan Kettering Cancer Center in New York, New York, Dr Milind Javle from The University of Texas MD Anderson Cancer Center in Houston, Texas, and Dr Robin K (Katie) Kelley from UCSF Helen Diller Family Comprehensive Cancer Center in San Francisco, California, summarize the treatment landscape for patients with biliary tract cancers and review recent advancements in the field, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/BTCThinkTank2024).
© 2020-2025 Ivy Podcast Discovery LLC
